Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Overview of attention for article published in Clinical Epigenetics, October 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 27 Dimensions

Readers on

mendeley: 29 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 4,578 followers.

RT @Lymphoma_Papers: Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with ne…

25 Oct 2020

Reply Repost Favourite

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma. #lymphoma #lymsm https://t.co/pk92Vm81cd

25 Oct 2020

Reply Repost Favourite

New article: Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma. https://t.co/1DeDmqrmwh #DLBCL #lymsm #hematology https://t.co/RVpUU7zDRA

25 Oct 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.